Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer.

Ni Y, Schmidt KR, Werner BA, Koenig JK, Guldner IH, Schnepp PM, Tan X, Jiang L, Host M, Sun L, Howe EN, Wu J, Littlepage LE, Nakshatri H, Zhang S.

Nat Commun. 2019 Jun 28;10(1):2860. doi: 10.1038/s41467-019-10743-7.

2.

Potassium channel activity controls breast cancer metastasis by affecting β-catenin signaling.

Breuer EK, Fukushiro-Lopes D, Dalheim A, Burnette M, Zartman J, Kaja S, Wells C, Campo L, Curtis KJ, Romero-Moreno R, Littlepage LE, Niebur GL, Hoskins K, Nishimura MI, Gentile S.

Cell Death Dis. 2019 Feb 21;10(3):180. doi: 10.1038/s41419-019-1429-0.

3.

Metabolomics of oncogene-specific metabolic reprogramming during breast cancer.

Dai C, Arceo J, Arnold J, Sreekumar A, Dovichi NJ, Li J, Littlepage LE.

Cancer Metab. 2018 Apr 3;6:5. doi: 10.1186/s40170-018-0175-6. eCollection 2018.

4.

Discoidin domain receptor 1 (DDR1) ablation promotes tissue fibrosis and hypoxia to induce aggressive basal-like breast cancers.

Takai K, Drain AP, Lawson DA, Littlepage LE, Karpuj M, Kessenbrock K, Le A, Inoue K, Weaver VM, Werb Z.

Genes Dev. 2018 Feb 1;32(3-4):244-257. doi: 10.1101/gad.301366.117. Epub 2018 Feb 26.

5.

The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance.

Suarez CD, Wu J, Badve SS, Sparano JA, Kaliney W, Littlepage LE.

Oncotarget. 2017 Jul 17;8(65):108534-108547. doi: 10.18632/oncotarget.19308. eCollection 2017 Dec 12.

6.

Tumor infiltrating leukocyte density is independent of tumor grade and molecular subtype in aggressive breast cancer of Western Kenya.

Sawe RT, Mining SK, Ofulla AV, Patel K, Guyah B, Chumba D, Prosperi JR, Kerper M, Shi Z, Sandoval-Cooper M, Taylor K, Badve S, Stack MS, Littlepage LE.

Trop Med Health. 2017 Aug 4;45:19. doi: 10.1186/s41182-017-0059-4. eCollection 2017.

7.

Bone: A Fertile Soil for Cancer Metastasis.

Coughlin TR, Romero-Moreno R, Mason DE, Nystrom L, Boerckel JD, Niebur G, Littlepage LE.

Curr Drug Targets. 2017;18(11):1281-1295. doi: 10.2174/1389450117666161226121650. Review.

PMID:
28025941
8.

Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells.

Richards KE, Zeleniak AE, Fishel ML, Wu J, Littlepage LE, Hill R.

Oncogene. 2017 Mar 30;36(13):1770-1778. doi: 10.1038/onc.2016.353. Epub 2016 Sep 26.

9.

Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration.

Sawe RT, Kerper M, Badve S, Li J, Sandoval-Cooper M, Xie J, Shi Z, Patel K, Chumba D, Ofulla A, Prosperi J, Taylor K, Stack MS, Mining S, Littlepage LE.

BMC Cancer. 2016 Mar 10;16:204. doi: 10.1186/s12885-016-2204-6.

10.

Patient-Derived Tumor Xenograft Models of Breast Cancer.

Suarez CD, Littlepage LE.

Methods Mol Biol. 2016;1406:211-23. doi: 10.1007/978-1-4939-3444-7_19.

PMID:
26820959
11.

Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha.

Frietze S, O'Geen H, Littlepage LE, Simion C, Sweeney CA, Farnham PJ, Krig SR.

BMC Genomics. 2014 Jun 24;15:520. doi: 10.1186/1471-2164-15-520.

12.

A role for matrix metalloproteinases in regulating mammary stem cell function via the Wnt signaling pathway.

Kessenbrock K, Dijkgraaf GJ, Lawson DA, Littlepage LE, Shahi P, Pieper U, Werb Z.

Cell Stem Cell. 2013 Sep 5;13(3):300-13. doi: 10.1016/j.stem.2013.06.005. Epub 2013 Jul 18.

13.

The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.

Littlepage LE, Adler AS, Kouros-Mehr H, Huang G, Chou J, Krig SR, Griffith OL, Korkola JE, Qu K, Lawson DA, Xue Q, Sternlicht MD, Dijkgraaf GJ, Yaswen P, Rugo HS, Sweeney CA, Collins CC, Gray JW, Chang HY, Werb Z.

Cancer Discov. 2012 Jul;2(7):638-51. doi: 10.1158/2159-8290.CD-12-0093. Epub 2012 May 10.

14.

Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression.

Littlepage LE, Sternlicht MD, Rougier N, Phillips J, Gallo E, Yu Y, Williams K, Brenot A, Gordon JI, Werb Z.

Cancer Res. 2010 Mar 15;70(6):2224-34. doi: 10.1158/0008-5472.CAN-09-3515. Epub 2010 Mar 9.

15.

GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model.

Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ, Pai SY, Ho IC, Werb Z.

Cancer Cell. 2008 Feb;13(2):141-52. doi: 10.1016/j.ccr.2008.01.011.

16.

CSN5 isopeptidase activity links COP9 signalosome activation to breast cancer progression.

Adler AS, Littlepage LE, Lin M, Kawahara TL, Wong DJ, Werb Z, Chang HY.

Cancer Res. 2008 Jan 15;68(2):506-15. doi: 10.1158/0008-5472.CAN-07-3060.

17.

The fibroblastic coconspirator in cancer progression.

Egeblad M, Littlepage LE, Werb Z.

Cold Spring Harb Symp Quant Biol. 2005;70:383-8. Review.

18.

Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability.

Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Nieto MA, Werb Z, Bissell MJ.

Nature. 2005 Jul 7;436(7047):123-7.

19.

Coevolution of cancer and stromal cellular responses.

Littlepage LE, Egeblad M, Werb Z.

Cancer Cell. 2005 Jun;7(6):499-500.

20.

Identification of phosphorylated residues that affect the activity of the mitotic kinase Aurora-A.

Littlepage LE, Wu H, Andresson T, Deanehan JK, Amundadottir LT, Ruderman JV.

Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15440-5. Epub 2002 Nov 6.

22.
23.

Phosphorylation of CPE binding factor by Eg2 regulates translation of c-mos mRNA.

Mendez R, Hake LE, Andresson T, Littlepage LE, Ruderman JV, Richter JD.

Nature. 2000 Mar 16;404(6775):302-7.

PMID:
10749216
24.

13C NMR analysis of the use of alternative donors to the tetrahydrofolate-dependent one-carbon pools in Saccharomyces cerevisiae.

Pasternack LB, Littlepage LE, Laude DA Jr, Appling DR.

Arch Biochem Biophys. 1996 Feb 1;326(1):158-65.

PMID:
8579365

Supplemental Content

Loading ...
Support Center